Tisocalcitate

Drug Profile

Tisocalcitate

Alternative Names: Psoriasis therapy - Bayer Schering Pharma

Latest Information Update: 22 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer Schering Pharma
  • Class Antipsoriatics; Vitamin D analogues
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Psoriasis

Most Recent Events

  • 29 Dec 2006 Schering AG is now called Bayer Schering Pharma AG
  • 03 Mar 2004 Data presented at the 62nd Annual Meeting of the American Academy of Dermatology (AAD-2004) have been added to the adverse events and pharmacokinetics sections ,
  • 12 May 2003 Phase-II clinical trials in Psoriasis in Europe (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top